Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children...
Read moreDetails